Edition:
India

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

5.05USD
24 Nov 2017
Change (% chg)

$-0.15 (-2.88%)
Prev Close
$5.20
Open
$5.23
Day's High
$5.27
Day's Low
$5.05
Volume
146,102
Avg. Vol
175,692
52-wk High
$15.01
52-wk Low
$4.10

Latest Key Developments (Source: Significant Developments)

Insys Therapeutics reports Q3 loss per share of $2.30
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Insys Therapeutics Inc :Insys therapeutics reports third quarter 2017 results.Q3 loss per share $2.30.Q3 revenue $48.9 million.Q3 revenue view $35.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Insys therapeutics inc qtrly ‍net revenue was unfavorably impacted by approximately $5 million due to product returns​.Insys therapeutics inc qtrly ‍ gross revenue was $48.9 million, resulting in net revenue of $30.7 million​.  Full Article

Insys Therapeutics provides update on NASDAQ trading hold
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Insys Therapeutics Inc ::Insys Therapeutics provides update on NASDAQ trading hold.Subsequent to trading hold placed on stock on Thursday after market close, received series of questions on Friday from NASDAQ​.Questions received from NASDAQ on Oct 27 have been addressed, co is awaiting response from NASDAQ regarding resumption of trading​.  Full Article

Insys Therapeutics reports preliminary estimated revenues from Subsys for Q3 2016 to be $54 mln -$55 mln
Thursday, 13 Oct 2016 

Insys Therapeutics Inc : Insys Therapeutics reports preliminary estimated revenues from subsys for the third quarter 2016 . Insys Therapeutics Inc - preliminary estimated revenues from Subsys (fentanyl sublingual spray) for Q3 of 2016 will be in range of $54 million to $55 million . Insys Therapeutics Inc- company believes it will be cash-flow positive at the level of sales . Insys Therapeutics Inc - "estimated revenues for quarter reflect a decline in prescriptions" .Insys Therapeutics-believes scrutiny resulted in patients having difficulty getting reimbursement for transmucosal immediate release fentanyl medications.  Full Article

Insys Therapeutics Q2 earnings per share $0.06
Wednesday, 3 Aug 2016 

Insys Therapeutics Inc : Q2 adjusted non-gaap earnings per share $0.13 . Q2 revenue $67.1 million versus i/b/e/s view $66.9 million . Insys therapeutics reports second quarter 2016 results . Q2 earnings per share $0.06 .Q2 earnings per share view $0.07 -- Thomson Reuters I/B/E/S.  Full Article

Insys Therapeutics announces FDA approval of Syndros
Tuesday, 5 Jul 2016 

Insys Therapeutics Inc : Syndros is currently awaiting scheduling by U.S. Drug Enforcement Administration . Company anticipates launching Syndros in second half of 2016 . Syndros is approved for use in treating anorexia associated with weight loss in patients with AIDS . Insys therapeutics announces FDA approval of Syndros .Syndros is also approved for use in treating nausea, vomiting associated cancer chemotherapy in patients.  Full Article

Kessler Topaz Meltzer & Check, LLP Files Shareholder Class Action Against Insys Therapeutics Inc - ACSWIR
Saturday, 6 Feb 2016 

Insys Therapeutics Inc:The law firm of Kessler Topaz Meltzer & Check, LLP announces that it has filed a shareholder class action lawsuit against Insys Therapeutics on behalf of purchasers of the Company's securitiesbetween March 3, 2015 and January 25, 2016 - ACSWIR.The shareholder class action complaint alleges that Insys and certain of its executive officers made a series of false and misleading statements, and failed to disclose material adverse facts, about the Company's business and operations to investors during the Class Period.Specifically, the defendants are alleged to have failed to disclose that the Company was engaged in the illegal and improper off-labeling marketing of Subsys;.certain Insys employees - including Defendant Michael L. Babich, the President and Chief Executive Officer of Insys during much of the Class Period - were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys.as a result, the Company's financial statements were materially false and misleading at all relevant times.  Full Article

Photo

Billionaire founder of Insys pleads not guilty to opioid bribe scheme

BOSTON The billionaire founder of drugmaker Insys Therapeutics Inc pleaded not guilty on Thursday to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based spray to treat pain in cancer patients.